Bora Group has announced it will acquire MacroGenics' GMP manufacturing operations, including its CDMO business, for $122.5m.
The transaction will include a biologics drug substance manufacturing facility located in Rockville, Maryland and an associated warehousing centre in Frederick, Maryland.
Bora added that it will sign a long-term CDMO Service Agreement with MacroGenics upon the closing of the acquisition and will leverage the Rockville Site in cooperation with Tanvex Biopharma, which operates the Group's biologics CDMO franchise under the "Bora Biologics" brand.
Together with Bora's sterile drug product capabilities, this is expected to scale the Group's end-to-end biologics platform.
The Rockville facility has been operating as an outsource manufacturing partner since 2022, featuring five 2000-litre and two 500-litre single-use bioreactors, along with integrated quality control and analytical labs.
Bora is set to take on a significant backlog for its Bora Biologics CDMO business, which includes commercial and clinical-stage monoclonal antibody programmes as well as a strong project pipeline.
Currently, commercial manufacturing represents more than half of the site's revenue.
"This acquisition marks a pivotal step in strengthening Bora's integrated biologics CDMO platform in the United States," said Bobby Sheng, Chair and CEO of Bora Group.
With the addition of the Rockville site, Bora Biologics total drug substance capacity would be 20,000 litres (SUB) and Bora Group will integrate our in-house DS (Drug Substance) and DP (Drug Product) capabilities and network investments during the next 12 to 18 months to offer global biotech customers a seamless offering, allowing customers to advance programmes from development through commercial supply with one single partner.